Good afternoon :)
Place Order
Add to Watchlist

Mankind Pharma Ltd

MANKIND

Mankind Pharma Ltd

MANKIND
Health CarePharmaceuticals
LargecapWith a market cap of ₹92,165 cr, stock is ranked 88
High RiskStock is 3.40x as volatile as Nifty
2,300.751.52% (-35.60)
2,300.751.52% (-35.60)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹92,165 cr, stock is ranked 88
High RiskStock is 3.40x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹92,165 cr, stock is ranked 88
High RiskStock is 3.40x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
53.3612.09
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.915.950.56%

Forecast & Ratings

Detailed Forecast 
58%
Analysts have suggested that investors can buy this stock

from 12 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Investor Presentation

View older 

Aug 2, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023TTM
Total Revenue5,987.196,397.067,992.048,890.4210,198.15
Raw Materialssubtract1,888.532,028.002,871.322,622.907,585.69
Power & Fuel Costsubtract79.9682.53103.13108.96
Employee Costsubtract1,335.531,415.781,620.591,918.47
Selling & Administrative Expensessubtract885.851,086.441,410.011,616.92
Operating & Other expensessubtract237.29-47.44-214.04580.25
Depreciation/Amortizationsubtract99.06118.97166.62325.92378.08
Interest & Other Itemssubtract23.2421.1659.8045.7629.31
Taxes & Other Itemssubtract407.31426.19541.12389.39477.96
EPS25.7231.5935.7832.0043.11
DPS0.007.600.000.000.00
Payout ratio0.000.240.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
FY 2024

Annual Report Pending

Investor Presentation

Aug 2PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Mankind Pharma Ltd71.9012.09
Sun Pharmaceutical Industries Ltd45.896.560.71%
Cipla Ltd43.135.100.57%
Dr Reddy's Laboratories Ltd22.754.400.65%

Price Comparison

Compare MANKIND with any stock or ETF
Compare MANKIND with any stock or ETF
MANKIND
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 2.56%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding76.50%7.55%2.23%6.74%6.97%

May 2023

Jun 2023

Sep 2023

Dec 2023

Shareholding History

SepMarMayJunSepDec '230.00%2.61%2.61%4.18%4.18%6.74%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 3.66%

Top 5 Mutual Funds holding Mankind Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI BLUE CHIP FUND DIRECT PL GROWTH

Growth
0.6504%1.38%0.71%30/57 (+11)
Axis ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.4545%1.23%0.24%29/57 (0)
Axis Bluechip Fund - Growth - Direct Plan

Growth
0.2812%0.79%0.79%32/56 (+22)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Mankind Pharma Ltd

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time

News & Opinions

Hmm, looks like data is unavailable here. Please come back after some time.